Amarin Corp Plc (AMRN)

[ziploc_1]

Nuke...A potential advantage of MND-2119(as opposed to Vascepa) is that a combo drug, using a statin plus MND-2119, might need be used only twice a day...or even only once a day....since the EPA in MND-2119 would be more easily absorbed by the patient's body, therefore allowing for a lower dose of the EPA in the gelatin capsule to produce the same effect...Using less EPA might even make the product cheaper to manufacture than Vascepa.

An as yet to be answered is whether Amarin would have to pay royalties to Mochida for the use of their product...in addition to the $2 million they paid up front to Mochida upon signing their collaboration agreement.